Home > BRISA > Search result
COVID-19

In this section you will find the HTA reports produced by RedETSA members in response to the COVID-19 pandemic. For additional resources, please visit PAHO’s website.


Limitation of Liability

The information, products, services, tools and/or opinions shared and expressed on the platform are the sole responsibility of the institutions that produce them, and do not necesarily represent the views of PAHO/WHO.

PAHO/WHO and its Specialized Center BIREME make no warranties nor guarantees the accuracy or truthfulness of the information, products, services and/or tools provided. Users must use these products, services and/or tools at their own risk. In no case will PAHO/WHO and its Specialized Center BIREME be liable for damages, even if they may have been warned and/or prevented.

Terms and conditions of use

Results: 1

Bedaquilina para pacientes com tuberculose resistentes à rifampicina, multirresistentes e extensivamente resistentes a medicamentos

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
INTRODUÇÃO: A tuberculose (TB), conhecida anteriormente como tísica, é uma doença que pode ser causada por sete espécies do gênero do complexo Mycobacterium sendo a mais importante, do ponto de vista de saúde pública, a M. tuberculosis. Globalmente cerca de 10 milhões de pessoas tiveram TB no a...
Tuberculosis, Multidrug-Resistant/drug therapy, Diarylquinolines/therapeutic use, Levofloxacin/therapeutic use, Moxifloxacin/therapeutic use, Amikacin/therapeutic use, Capreomycin/therapeutic use, Ethionamide/therapeutic use, Linezolid/therapeutic use, Clofazimine/therapeutic use, Pyrazinamide/therapeutic use, Isoniazid/therapeutic use, Rifampin/therapeutic use, Aminosalicylic Acid/therapeutic use, Technology Assessment, Biomedical, Cost-Benefit Analysis/economics, Unified Health System, Brazil
Fulltext